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SUMMARY 
Pharmaceutical drugability of peptide drugs 
by analytical characterisation.
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Peptide drugs gain increased interest as a new supra-group of therapeutics between the classic-organic, small-molecule drugs and the large biotechnology-derived bio-drugs. 
They are used in different therapeutic or diagnostic areas like allergy, anti-infection, oncology, obesity, etc… but also as functional excipients (e.g. CPPs). Due to their particular 
structure and biochemical origin, the pharmaceutical development of a peptide drug poses special challenges.
After the initial synthesis of the active pharmaceutical ingredient (API) or functional excipient, analytical characterisation is aimed at integrity and purity evaluation of the 
compound, which is also required for initial biomedical experiments. In this analytical characterisation, sample treatment issues like solubility, adsorption and degradation are 
important  aspects to be looked after. The chemical and metabolic stability, critical parameters for peptides, is to be assessed to obtain kinetic and mechanistic information. 
Functionality is tested in-vitro, using cell- and organ-based protocols including ligand binding studies, as well as in-vivo encompassing  ADME and target-organ confirmation like 
brain behaviour.
The pharmaceutical drugability information thus obtained allows further development decisions including required drug modifications, synthesis and purification modifications, 
quality specification settings as well as proof-of-principle drug delivery formulations.
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Potential peptide drug
 HTS by LC-MSn [1]: from general pep-gradient :
to peptide-specific optimised gradient :
identity: must: e.g. m/h-obestatin: 1 of 5 suppliers: was NOT ob [2]
LC-MS required (not LC-UV only)
purity: preferably ≥ 95%, but minimally ≥ 90%:
solubilization and adsorption (more for iodinated radio-peptides)
 Stability: chemical under various conditions [1], 
incl. ligand binding conditions :
metabolic in blood and different tissues [4], e.g. obestatin in brain:
 Functionality: cellular response, receptor-binding and in-vivo distribution, e.g. mouse-SPECT: 
Drugability information                    development decisions
RESULTS 
Stability of FPKPEGSQDKSLHN in radioligand binding study incubation buffer
37°C
HEPES 20 mM pH 7.4 +
1 mg/ml BSA &
5 µl/ml PIC (in DMSO)
1st order kinetics
kobs = 0.10 hours
-1
t1/2 = ca 7 hours
y = 89.853e-0.109x
R² = 0.9962
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Total ≥ 1.00%
Mouse obestatin
GLB 9.07 5.37 8 2
CPR 0.38 0.12 5 0
GPS 3.90 0.71 14 0
Human obestatin
GLB 7.26 2.65 6 3
CPR 0.34 0.19 3 0
GPS 6.91 1.66 12 3
PB 0.67 0.17 7 0
PP 6.82 1.99 7 4
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Protease inhibitor (PI)
Half-life (min) [LC-UV mouse obestatin]
Crude brain homogenate
Brain membranes 
homogenate
No PI present 19 27
P8340 Protease Inhibitor Cocktail 52 74
EDTA 38 57
Soybean Trypsin Inhibitor 20 37
APMSF 20 15
1,10-Phenanthrolin 24 27
Captopril 20 27
Chymostatin 17 28
